Hidalgo-Vega, Á., Villoro, R., Blasco, J. A., Talavera, P., Ferro, B., & Purcaru, O. (2015). Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain. Cost Eff Resour Alloc.

Hidalgo-Vega, Álvaro, Renata Villoro, Juan Antonio Blasco, Pablo Talavera, Belén Ferro, και Oana Purcaru. "Cost-utility Analysis of Certolizumab Pegol Versus Alternative Tumour Necrosis Factor Inhibitors Available for the Treatment of Moderate-to-severe Active Rheumatoid Arthritis in Spain." Cost Eff Resour Alloc 2015.

Hidalgo-Vega, Álvaro, et al. "Cost-utility Analysis of Certolizumab Pegol Versus Alternative Tumour Necrosis Factor Inhibitors Available for the Treatment of Moderate-to-severe Active Rheumatoid Arthritis in Spain." Cost Eff Resour Alloc 2015.